Description
Febout 40 mg Tablet, manufactured by Radiant Pharmaceuticals Ltd., contains Febuxostat, a selective xanthine oxidase (XO) inhibitor used for the chronic management of hyperuricemia in patients with gout. Febuxostat works by inhibiting the enzyme xanthine oxidase, which is responsible for converting hypoxanthine and xanthine into uric acid. By reducing uric acid production, Febout helps prevent gout attacks and complications associated with hyperuricemia. The recommended starting dose is 40 mg once daily. If serum uric acid levels remain above 6 mg/dL after 2 weeks, the dose may be increased to 80 mg once daily. Febout can be taken with or without food and does not require dose adjustments in patients with mild to moderate renal or hepatic impairment. Common side effects may include gout flares, liver function abnormalities, nausea, headache, rash, and edema. Febout is contraindicated in patients receiving azathioprine, mercaptopurine, or theophylline due to potential drug interactions. Prophylactic therapy with NSAIDs or colchicine is recommended upon initiation to prevent gout flares. As with all medications, Febout should be used under the guidance of a healthcare professional.
60 MG.jpeg)
 20MG.jpeg)
 2GM.jpeg)
 10MG.jpeg)
 1GM.jpeg)
 ..jpeg)
.jpeg)
 ..jpeg)
 25MG.jpeg)
Change Language